NovoCure (NVCR) Competitors

NovoCure (NASDAQ:NVCR) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations.

Does the MarketBeat Community favor NVCR or STVN?

NovoCure received 447 more outperform votes than Stevanato Group when rated by MarketBeat users. However, 63.27% of users gave Stevanato Group an outperform vote while only 62.98% of users gave NovoCure an outperform vote.

Company	Underperform	Outperform
NovoCure	Outperform Votes 478 62.98%	Underperform Votes 281 37.02%
Stevanato Group	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%

Do analysts rate NVCR or STVN?

NovoCure currently has a consensus target price of $32.83, indicating a potential upside of 85.34%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Is NVCR or STVN more profitable?

Stevanato Group has a net margin of 10.47% compared to NovoCure's net margin of -25.93%. Stevanato Group's return on equity of 9.86% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.93%	-41.48%	-12.74%
Stevanato Group	10.47%	9.86%	5.79%

Do insiders & institutionals believe in NVCR or STVN?

84.6% of NovoCure shares are owned by institutional investors. 6.3% of NovoCure shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media prefer NVCR or STVN?

In the previous week, NovoCure had 10 more articles in the media than Stevanato Group. MarketBeat recorded 16 mentions for NovoCure and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.18 beat NovoCure's score of 0.53 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive
Stevanato Group	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation and earnings, NVCR or STVN?

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$621.71M	3.18	-$207.04M	-$1.51	-11.73
Stevanato Group	$1.10B	5.74	$157.62M	$0.48	43.56

Which has more risk & volatility, NVCR or STVN?

NovoCure has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Summary

Stevanato Group beats NovoCure on 12 of the 18 factors compared between the two stocks.